Avego

2023年6月1日

分享這篇文章提供的新聞分享這篇文章漢密爾頓,6月1日2023年AtomVie從全球Radiopharma Inc . (AtomVie),一個全球領先CDMO GMP製造和全球分銷的放射性藥物,今天宣布關閉其筆2係列融資由目前的投資者,Avego管理有限責任公司(“Avego”)。隨著筆1關閉2022年8月,AtomVie已經籌集到90美元,數量足以完成擴建和裝備64000平方英尺特製的,先進的,可伸縮的設施。Avego管理、公司商標“我們非常高興地與Avego擴大我們的關係。這項投資凝固AtomVie作為世界級的地位CDMO放射性藥物的臨床和商業生產,服務我們的客戶和改善全世界成千上萬的患者的生命。2024年末的新設施的跡象,我們興奮地宣布,目前預售製造能力”AtomVie首席執行官帕奎因布魯諾說。與世界級的員工及其在放射性藥物行業深入的經驗,AtomVie賦予下一代全球放射療法的發展。“Avego高興地擴大其與AtomVie合作,協作,凸顯我們對增長和創新的承諾。AtomVie的新設施,將開放在2024年末,將處理有意義的臨床可用的製造能力和商業計劃和預訂今天“Avego合夥人凱文·麥克尼爾說。AtomVie將展示2023年SNMMI年會,在進一步凸顯了其新工廠將於2024年亮相展台#。 About AtomVie Global Radiopharma Inc. ("AtomVie"): AtomVie, a spinout of the Centre for Probe Development and Commercialization (CPDC), is a global leading CDMO for the GMP manufacturing and global distribution of clinical and commercial radiopharmaceuticals. Building upon the expertise and high-quality services since 2008 from CPDC, AtomVie offers the full range of scientific, technical, regulatory, quality, logistics and business expertise combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. AtomVie currently serves international clients conducting studies in over 17 countries worldwide. About Avego Management, LLC ("Avego"): Avego, founded in 2015 by former healthcare entrepreneurs, is a multi-strategy healthcare-focused investment firm with offices in Georgia and New York. Through its three strategies, which include private equity, venture capital, and a hedge fund, Avego invests in private and public companies developing and commercializing innovative products and services for patients, practitioners, and other stakeholders across the healthcare continuum. To learn more about Avego, visit www.avego.com or contact: [email protected] .